Tag: janney-capital
-
UniQure shares jump on promising gene therapy data
Dutch biotech UniQure NV said its experimental gene therapy for a blood disorder benefited some patients in an early-stage study, offering a rare ray of hope in gene therapy research plagued by a series of failed trials. Janney Capital Markets analyst Debjit Chattopadhyay said UniQure’s data looked better than that of Baxalta Inc’s rival drug.…